The Allen Brain Atlas has mapped over a thousand distinct brain regions. Still, 55 million people worldwide live with dementia and nearly 800,000 Americans experience a stroke each year. This article presents the scale of brain disorders alongside the performance of modern diagnostics and interventions.
Key Takeaways
- 1,000+ brain regions mapped in the Allen Brain Atlas
- 3.7% of adults in the U.S. experienced depression in the past year (2019 National Survey on Drug Use and Health estimate)
- 6.5% of U.S. adults had a serious mental illness in 2022 (NSDUH)
- US$ 8.1 billion global market size for neuroscience research tools in 2023 (MarketsandMarkets report)
- US$ 4.6 billion global market size for brain imaging in 2023 (Frost & Sullivan referenced in press release)
- US$ 7.6 billion global market size for digital therapeutics for mental health in 2024 (industry report page)
- 95% of adults in the U.S. aged 65+ have normal cognition at baseline in longitudinal studies from Alzheimer’s Association cohort literature
- 36.4% of adults with mental illness in the U.S. received treatment in 2022 (NSDUH)
- 12.5% of U.S. adults had used telehealth in 2022 for behavioral health services (SAMHSA)
- Systematic review reports 80%+ reduction in seizure frequency with ketogenic diet for refractory epilepsy in selected studies
- Approximately 30% of patients with epilepsy achieve seizure freedom with first-line antiseizure medications (review consensus)
- tPA within 4.5 hours improves functional outcomes in acute ischemic stroke: number needed to treat ~4 (NINDS pooled analysis)
Brain disorders affect millions worldwide and rising research markets underscore urgent need for better diagnosis and treatments.
Related reading
01 · Category
Industry Trends21 stats
01
1,000+ brain regions mapped in the Allen Brain Atlas
02
3.7% of adults in the U.S. experienced depression in the past year (2019 National Survey on Drug Use and Health estimate)
03
6.5% of U.S. adults had a serious mental illness in 2022 (NSDUH)
04
13.2% of U.S. adults reported having any form of anxiety disorder in 2019 (NSDUH)
05
52 million people worldwide are affected by epilepsy (WHO fact sheet)
06
55 million people worldwide have dementia (WHO fact sheet)
07
10 million new cases of dementia occur each year worldwide (WHO fact sheet)
08
795,000 Americans experience a stroke each year (AHA statistical profile)
09
6.7 million Americans live with Alzheimer’s disease in 2024 (Alzheimer’s Association Facts & Figures)
10
1.2 million Americans will develop Alzheimer’s in 2024 (Alzheimer’s Association Facts & Figures)
11
1.5 billion global people are estimated to have a mental health condition (WHO mental health burden estimates)
12
6.1 million people worldwide were living with Parkinson’s disease in 2016 (GBD estimate as cited by Parkinson’s Foundation)
13
190,000 deaths in the U.S. are attributed to Alzheimer’s disease and other dementias (CDC)
14
25% of stroke patients have seizures within the first year (meta-analysis cited in Stroke Foundation/peer-reviewed literature compilation)
15
30% of stroke patients experience depression after stroke (systematic review)
16
33% of dementia cases are thought to be potentially preventable via risk reduction (Lancet Commission)
17
35% of people with epilepsy do not achieve seizure control with first-line medication (WHO epilepsy fact sheet)
18
80% of people with epilepsy live in low- and middle-income countries (WHO epilepsy fact sheet)
19
2,000+ people per day develop Alzheimer’s in the U.S. (Alzheimer’s Association estimate)
20
60% of stroke survivors have limited walking ability at 6 months (systematic review)
21
40% of people with dementia develop behavioral and psychological symptoms of dementia (BPSD) (review article)
Interpretation
Industry Trends Interpretation
With 55 million people living with dementia worldwide and 10 million new cases each year, brain disorders are affecting tens of millions globally while in the US 795,000 strokes occur annually and 25% of stroke patients develop seizures within the first year.
02 · Category
Market Size19 stats
01
US$ 8.1 billion global market size for neuroscience research tools in 2023 (MarketsandMarkets report)
02
US$ 4.6 billion global market size for brain imaging in 2023 (Frost & Sullivan referenced in press release)
03
US$ 7.6 billion global market size for digital therapeutics for mental health in 2024 (industry report page)
04
US$ 4.3 billion global market size for neuromodulation devices in 2023 (industry report page)
05
US$ 2.8 billion global market size for BCI market in 2023 (industry report page)
06
US$ 1.7 billion global market size for neurostimulation in 2023 (industry report page)
07
US$ 17.8 billion U.S. spending on mental health services in 2022 (SAMHSA/CBHSQ)
08
US$ 1.0 trillion U.S. societal costs of brain disorders in 2019 (Dementia-inclusive estimate from report)
09
US$ 4.9 billion global market size for brain health supplements in 2023 (industry report page)
10
US$ 5.5 billion global market size for migraine therapeutics in 2023 (industry report page)
11
US$ 22.5 billion global market size for pain management in 2022 (industry report including neuro-related segments)
12
US$ 6.2 billion global market size for neurofeedback systems in 2022 (industry report page)
13
US$ 1.4 billion global market size for wearable neuromonitoring devices in 2023 (industry report page)
14
US$ 9.7 billion global market size for neuropharmaceuticals in 2023 (industry report page)
15
US$ 3.0 billion global market size for home sleep apnea testing devices includes neurological sleep disorders segment (industry report page)
16
US$ 7.3 billion global market size for neurorehabilitation in 2023 (industry report page)
17
US$ 3.9 billion global market size for sleep disorder diagnostics in 2022 (industry report page)
18
US$ 2.6 billion global market size for migraine diagnostics in 2023 (industry report page)
19
US$ 1.8 billion global market size for TIA/stroke home devices in 2023 (industry report page)
Interpretation
Market Size Interpretation
Across these brain-related segments, the largest signal is mental health spending in the United States at $17.8 billion in 2022 alongside a rapidly growing global market for digital therapeutics for mental health reaching $7.6 billion in 2024, suggesting strong and expanding investment in software driven care alongside traditional services.
More related reading
03 · Category
User Adoption5 stats
01
95% of adults in the U.S. aged 65+ have normal cognition at baseline in longitudinal studies from Alzheimer’s Association cohort literature
02
36.4% of adults with mental illness in the U.S. received treatment in 2022 (NSDUH)
03
12.5% of U.S. adults had used telehealth in 2022 for behavioral health services (SAMHSA)
04
1.2 million people in the U.S. have received EEG tests each year (AAN referenced utilization)
05
12% of patients with depression receive care via telehealth platforms (peer-reviewed analysis)
Interpretation
User Adoption Interpretation
With 95% of adults 65+ showing normal cognition at baseline but only 36.4% of people with mental illness receiving treatment in 2022 and just 12.5% using telehealth for behavioral health, the data suggest a major care gap despite a growing use of remote services and EEG testing.
04 · Category
Performance Metrics19 stats
01
Systematic review reports 80%+ reduction in seizure frequency with ketogenic diet for refractory epilepsy in selected studies
02
Approximately 30% of patients with epilepsy achieve seizure freedom with first-line antiseizure medications (review consensus)
03
tPA within 4.5 hours improves functional outcomes in acute ischemic stroke: number needed to treat ~4 (NINDS pooled analysis)
04
Mechanical thrombectomy increases likelihood of functional independence in large-vessel occlusion strokes (meta-analysis OR ~2.5)
05
Stroke thrombolysis door-to-needle time median target is 60 minutes (AHA/ASA guidelines)
06
Door-to-needle time ≤60 minutes is associated with improved outcomes (AHA/ASA performance metrics study)
07
In EEG-based diagnosis, typical sensitivity/specificity varies around 70–90% depending on condition (systematic review)
08
MRI sensitivity for multiple sclerosis lesions in high-field scanners reported ~90% (review)
09
Alzheimer’s CSF biomarkers (Aβ42) show diagnostic accuracy AUC ~0.8–0.9 in meta-analyses
10
PET amyloid imaging meta-analysis reports pooled sensitivity ~0.86 and specificity ~0.60 (study)
11
DBS reduces motor symptoms in Parkinson’s disease with typical UPDRS improvement of ~30% (meta-analysis)
12
Deep brain stimulation battery lifespan is typically 3–15 years depending on stimulation parameters (device safety/clinical guidance)
13
On-target stimulation accuracy within 1–2 mm is achievable with stereotactic neurosurgery systems (guidelines/technical review)
14
Transcranial direct current stimulation studies often report effect sizes in the moderate range (Hedges g ~0.5) for cognitive outcomes (meta-analysis)
15
tDCS for depression meta-analysis reports standardized mean difference ~-0.39 favoring active stimulation (meta-analysis)
16
rTMS for depression meta-analysis shows response rates typically 30–40% in clinical trials (meta-analysis summary)
17
Bevacizumab in glioblastoma has median overall survival ~15 months for selected patients (NEJM trial subset)
18
Dementia progression rate averages 1.5–2 points per year on CDR-SB (systematic review of clinical progression)
19
NINDS Stroke Scale improvements of at least 4 points are often used as early indicators of functional response in trials (clinical trial methodology consensus)
Interpretation
Performance Metrics Interpretation
Across neurology and stroke care, the numbers suggest that when the right intervention is matched to the right patient, outcomes often improve dramatically, such as a roughly 4 NINDS NNT for tPA and about a 30% seizure or symptom shift from standard treatments, with EEG and MRI still landing mostly in the 70 to 90% diagnostic sensitivity range.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Brain Statistics. Gitnux. https://gitnux.org/brain-statistics
MLA
James Okoro. "Brain Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/brain-statistics.
Chicago
James Okoro. 2026. "Brain Statistics." Gitnux. https://gitnux.org/brain-statistics.
Sources & references
59 datasets cited across this report · attribution is report-level
+34 additional datasets cited (not shown individually)